MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer

Oncogene

Volumn 25, Issue 21, 2006, Pages 2987-2998

  Xu, L ^b   Chen, S ^b   Bergan, R C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

Heat shock protein 27; Invasion; Matrix metalloproteinase 2; Mitogen activated protein kinase activated protein kinase 2; Prostate cancer; Transforming growth factor

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; GELATINASE A; HEAT SHOCK PROTEIN 27; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE ACTIVATED PROTEIN KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROFADOL; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; CELL INVASION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME SUBSTRATE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; WILD TYPE;

ADENOCARCINOMA; CELL LINE, TUMOR; ENZYME ACTIVATION; HEAT-SHOCK PROTEINS; HUMANS; IMIDAZOLES; MALE; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS; PROTEIN KINASES; PYRIDINES; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 33646859435     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209337     Document Type: Article

References (33)

1. Aldrian S, Trautinger F, Frohlich I, Berger W, Micksche M, Kindas-Mugge I. (2002). Cell Stress Chaperones 7: 177-185.
2. Attisano L, Wrana JL. (2002). Science 296: 1646-1647.
3. Carroll PR, Lee KL, Fuks ZY, Kantoff PW. (2001). In: DeVita VT, Hellman S, Rosenberg SA (eds). CANCER: Principals and Practices of Oncology. Lippincott-Raven: New York, pp 1418-1479.
4. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M et al. (2000). Cancer Res 60: 7099-7105.
5. Gerthoffer WT, Gunst SJ. (2001). J Appl Physiol 91: 963-972.
6. Guay J, Lambert H, Gingras-Breton G, Lavoie JN, Huot J, Landry J. (1997). J Cell Sci 110(Part 3): 357-368.
7. Hansen RK, Parra I, Hilsenbeck SG, Himelstein B, Fuqua SA. (2001). Biochem Biophys Res Commun 282: 186-193.
8. Hatakeyama D, Kozawa O, Niwa M, Matsuno H, Ito H, Kato K et al. (2002). Biochim Biophys Acta 1589: 15-30.
9. Hayes SA, Huang X, Kambhampati S, Platanias LC, Bergan RC. (2003). Oncogene 22: 4841-4850.
10. Hedges JC, Dechert MA, Yamboliev IA, Martin JL, Hickey E, Weber LA et al. (1999). J Biol Chem 274: 24211-24219.
11. Huang X, Chen S, Xu L, Liu YQ, Deb DK, Platanias LC et al. (2005). Cancer Res 65: 3470-3478.
12. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. (2005). CA Cancer J Clin 55: 10-30.
13. Kotlyarov A, Yannoni Y, Fritz S, Laass K, Telliez JB, Pitman D et al. (2002). Mol Cell Biol 22: 4827-4835.
14. Krump E, Sanghera JS, Pelech SL, Furuya W, Grinstein S. (1997). J Biol Chem 272: 937-944.
15. Liu Y, Jovanovic B, Pins M, Lee C, Bergan RC. (2002). Oncogene 21: 8272-8281.
16. Liu YQ, Kyle E, Patel S, Housseau F, Hakim F, Lieberman R et al. (2001). Prostate Cancer Prostatic Dis 4: 81-91.
17. Liu YU, Kyle E, Lieberman R, Crowell J, Kelloff G, Bergan RC. (2000). Clin Exp Metast 18: 203-212.
18. Ludwig S, Engel K, Hoffmeyer A, Sithanandam G, Neufeld B, Palm D et al. (1996). Mol Cell Biol 16: 6687-6697.
19. Munshi HG, Wu YI, Mukhopadhyay S, Ottaviano AJ, Sassano A, Koblinski JE et al. (2004). J Biol Chem 279: 39042-39050.
20. Platanias LC. (2003). Blood 101: 4667-4679.
21. Ravanti L, Hakkinen L, Larjava H, Saarialho-Kere U, Foschi M, Han J et al. (1999). J Biol Chem 274: 37292-37300.
22. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L et al. (2004). Cancer Res 64: 6595-6602.
23. Ruoslahti E. (1996). Sci Am 275: 72-77.
24. Schafer C, Clapp P, Welsh MJ, Benndorf R, Williams JA. (1999). Am J Physiol 277: C1032-C1043.
25. Schwartz GN, Liu YQ, Tisdale J, Walshe K, Fowler D, Gress R et al. (1998). Antisense Nucleic Acid Drug Dev 8: 329-339.
26. Shi Y, Massague J. (2003). Cell 113: 685-700.
27. Sporn MB. (1996). Lancet 347: 1377-1381.
28. Stokoe D, Campbell DG, Nakielny S, Hidaka H, Leevers SJ, Marshall C et al. (1992a). EMBO J 11: 3985-3994.
29. Stokoe D, Engel K, Campbell DG, Cohen P, Gaestel M. (1992b). FEBS Lett 313: 307-313.
30. Tong L, Pav S, White DM, Rogers S, Crane KM, Cywin CL et al. (1997). Nat Struct Biol 4: 311-316.
31. Wilson KP, McCaffrey PG, Hsiao K, Pazhanisamy S, Galullo V, Bemis GW et al. (1997). Chem Biol 4: 423-431.
32. Winzen R, Kracht M, Ritter B, Wilhelm A, Chen CY, Shyu AB et al. (1999). EMBO J 18: 4969-4980.
33. Woodhouse EC, Chuaqui RF, Liotta LA. (1997). Cancer 80: 1529-1537.